HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 4 matching records:

Displaying record number 57300

HXB2 Location  Gag(76-86)   Gag Epitope Map
View variants at this location
Epitope RSLYNTVATLY   Epitope Alignment
Variants
RSLYNTiATLY   diminished response; escape documented in this paper
RSLYNTVAvLY   diminished response; escape documented in this paper
RSLYNTiAvLY   diminished HLA binding or increased off-rate; diminished response; escape documented in this paper
RSLfNTiATLY   diminished HLA binding or increased off-rate; diminished response; escape documented in this paper
RSLfNTVATLY   diminished HLA binding or increased off-rate; diminished response; escape documented in this paper
RSLfNTVAvLY   diminished HLA binding or increased off-rate; diminished response; escape documented in this paper
RSLfNTiAvLY   diminished HLA binding or increased off-rate; diminished response; escape documented in this paper
kSLYNTVATLY   diminished HLA binding or increased off-rate; diminished response
kSLYNTVAvLY   diminished HLA binding or increased off-rate; diminished response; escape documented in this paper
kSLYNTiATLY   diminished response; escape documented in this paper
kSLYNTiAvLY   diminished HLA binding or increased off-rate; diminished response; escape documented in this paper
kSLfNTVATLY   diminished HLA binding or increased off-rate; diminished response; escape documented in this paper
kSLfNTiATLY   diminished HLA binding or increased off-rate; diminished response; escape documented in this paper
kSLfNTVAvLY   diminished HLA binding or increased off-rate; diminished response; escape documented in this paper
kSLfNTiAvLY   diminished HLA binding or increased off-rate; diminished response; escape documented in this paper
Epitope Name RY11
Species (MHC/HLA human(A*02:01, A*30:02)

Variant Details

Showing all: 15 variant(s).


Variant ID.  2973
Epitope Seq.  RSLYNTVATLY
Variant Seq.  RSLYNTiATLY
Mutations V/I
Epitope Location V7I
HXB2 Location V82I
Mutation Type DR: diminished response
E: escape documented in this paper
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant RSLYNTiATLY had a large increase in binding to HLA-A*02 in vitro, but it showed a significant decrease in ex-vivo EliSpot responses in 3/3 chronically-infected, untreated patients as compared to wt RY11. The authors designate V82I mutation-containing peptides to be escapes.


Variant ID.  2974
Epitope Seq.  RSLYNTVATLY
Variant Seq.  RSLYNTVAvLY
Mutations T/V
Epitope Location T9V
HXB2 Location T84V
Mutation Type DR: diminished response
E: escape documented in this paper
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant RSLYNTVAvLY bound at the same Kd to HLA-A*02 as to the WT sequence, but EliSpot response in 2/3 chronically-infected, untreated patients was abolished. Slightly diminished response was seen in one patient. The authors designate T84V mutation-containing peptides as escapes.


Variant ID.  2975
Epitope Seq.  RSLYNTVATLY
Variant Seq.  RSLYNTiAvLY
Mutations V/I T/V
Epitope Location V7I T9V
HXB2 Location V82I T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
DR: diminished response
E: escape documented in this paper
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant RSLYNTiAvLY did not bind to HLA-A*02 in vitro, and it showed complete abrogation of ex-vivo EliSpot responses in 1/3 chronically-infected, untreated patients; diminished response in another patient; and no change in the third as compared to WT RY11. The authors designate both V82I and T84V mutation-containing peptides to be escapes.


Variant ID.  2976
Epitope Seq.  RSLYNTVATLY
Variant Seq.  RSLfNTiATLY
Mutations Y/F V/I
Epitope Location Y4F V7I
HXB2 Location Y79F V82I
Mutation Type DHB: diminished HLA binding or increased off-rate
DR: diminished response
E: escape documented in this paper
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant RSLfNTiATLY did not bind to HLA-A*02, and it showed a significant decrease in ex-vivo EliSpot response in 2 chronically-infected, untreated patients, with no changes in 1 patient as compared to WT RY11. The authors designate Y79F or V82I mutation-containing peptides as escapes.


Variant ID.  2977
Epitope Seq.  RSLYNTVATLY
Variant Seq.  RSLfNTVATLY
Mutations Y/F
Epitope Location Y4F
HXB2 Location Y79F
Mutation Type DHB: diminished HLA binding or increased off-rate
DR: diminished response
E: escape documented in this paper
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant RSLfNTVATLY did not bind to HLA-A*02 in vitro, and it showed a decrease in ex-vivo EliSpot response in 2/3 chronically-infected, untreated patients as compared to wt RY11. The authors designate Y79F mutation-containing peptides to be escapes.


Variant ID.  2978
Epitope Seq.  RSLYNTVATLY
Variant Seq.  RSLfNTVAvLY
Mutations Y/F T/V
Epitope Location Y4F T9V
HXB2 Location Y79F T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
DR: diminished response
E: escape documented in this paper
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant RSLfNTVAvLY did not bind to HLA-A*02 in vitro, and it showed a significant decrease in ex-vivo EliSpot response in 1 chronically-infected, untreated patient; abrogation of CTL response in another such patient; with no changes in the third patient when compared to wt RY11. The authors designate Y79F and T84V mutation-containing peptides to be escapes.


Variant ID.  2979
Epitope Seq.  RSLYNTVATLY
Variant Seq.  RSLfNTiAvLY
Mutations Y/F V/I T/V
Epitope Location Y4F V7I T9V
HXB2 Location Y79F V82I T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
DR: diminished response
E: escape documented in this paper
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant RSLfNTiAvLY did not bind to HLA-A*02 in vitro, and it showed a decrease in ex-vivo EliSpot response in 1/3 chronically-infected, untreated patients; with abrogation of CTL response in 1 other patient; and a slight increase for the last patient as compared with WT RY11. The authors designate Y79F, V82I or T84V mutation-containing peptides to be escapes.


Variant ID.  2980
Epitope Seq.  RSLYNTVATLY
Variant Seq.  kSLYNTVATLY
Mutations R/K
Epitope Location R1K
HXB2 Location R76K
Mutation Type DHB: diminished HLA binding or increased off-rate
DR: diminished response
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant kSLfNTiATLY did not bind to HLA-A*02 in vitro, but it showed a decrease in ex-vivo EliSpot response in 2/3 chronically-infected, untreated patients as compared to WT RY11.


Variant ID.  2981
Epitope Seq.  RSLYNTVATLY
Variant Seq.  kSLYNTVAvLY
Mutations R/K T/V
Epitope Location R1K T9V
HXB2 Location R76K T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
DR: diminished response
E: escape documented in this paper
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant kSLYNTVAvLY had loss of binding to HLA-A*02 in vitro; and it showed a significant decrease in ex-vivo EliSpot response in 1 chronically-infected, untreated patient, and abrogation of CTL responses in the other 2.


Variant ID.  2982
Epitope Seq.  RSLYNTVATLY
Variant Seq.  kSLYNTiATLY
Mutations R/K V/I
Epitope Location R1K V7I
HXB2 Location R76K V82I
Mutation Type DR: diminished response
E: escape documented in this paper
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant kSLYNTiATLY had an increase in binding to HLA-A*02 in vitro; but it showed a significant decrease in EliSpot response in 1 chronically-infected, untreated patient; abrogation of CTL responses in the second patient; and no change in the third when compared to wt RY11. The authors designate V82I mutation-containing peptides to be escapes.


Variant ID.  2983
Epitope Seq.  RSLYNTVATLY
Variant Seq.  kSLYNTiAvLY
Mutations R/K V/I T/V
Epitope Location R1K V7I T9V
HXB2 Location R76K V82I T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
DR: diminished response
E: escape documented in this paper
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant kSLYNTiAvLY lost binding to HLA-A*02 in vitro; and it showed a significant decrease in ex-vivo EliSpot response in 2 chronically-infected, untreated patients and abrogation of CTL response in the third. The authors designate V82I or T84V mutation-containing peptides as escapes.


Variant ID.  2984
Epitope Seq.  RSLYNTVATLY
Variant Seq.  kSLfNTVATLY
Mutations R/K Y/F
Epitope Location R1K Y4F
HXB2 Location R76K Y79F
Mutation Type DHB: diminished HLA binding or increased off-rate
DR: diminished response
E: escape documented in this paper
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant kSLfNTVATLY lost binding to HLA-A*02 in vitro; and it showed a significant decrease in ex-vivo EliSpot response in 3/3 chronically-infected, untreated patients. The authors designate Y79F mutation-containing peptides as escapes.


Variant ID.  2985
Epitope Seq.  RSLYNTVATLY
Variant Seq.  kSLfNTiATLY
Mutations R/K Y/F V/I
Epitope Location R1K Y4F V7I
HXB2 Location R76K Y79F V82I
Mutation Type DHB: diminished HLA binding or increased off-rate
DR: diminished response
E: escape documented in this paper
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant kSLfNTiATLY lost binding to HLA-A*02 in vitro; and it showed a significant decrease in ex-vivo EliSpot responses in 3/3 chronically-infected, untreated patients as compared to wt RY11. The authors designate Y79F or V82I mutation-containing peptides as escapes.


Variant ID.  2986
Epitope Seq.  RSLYNTVATLY
Variant Seq.  kSLfNTVAvLY
Mutations R/K Y/F T/V
Epitope Location R1K Y4F T9V
HXB2 Location R76K Y79F T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
DR: diminished response
E: escape documented in this paper
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant kSLfNTVAvLY lost binding to HLA-A*02 in vitro; and it showed a significant decrease in EliSpot response in 2 chronically-infected, untreated patients; and abrogation of CTL response in the third. The authors designate Y79F or T84V mutation-containing peptides as escapes.


Variant ID.  2987
Epitope Seq.  RSLYNTVATLY
Variant Seq.  kSLfNTiAvLY
Mutations R/K Y/F V/I T/V
Epitope Location R1K Y4F V7I T9V
HXB2 Location R76K Y79F V82I T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
DR: diminished response
E: escape documented in this paper
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant kSLfNTiAvLY did not bind to HLA-A*02 in vitro, and it showed a decrease in ex-vivo EliSpot response in 1/3 chronically-infected, untreated patients, with abrogation of CTL response in the other 2 patients as compared to WT RY11. The authors designate Y79F, V82I or T84V mutation-containing peptides to be escapes.

References

Tenzer2009 Stefan Tenzer, Edmund Wee, Anne Burgevin, Guillaume Stewart-Jones, Lone Friis, Kasper Lamberth, Chih-hao Chang, Mikkel Harndahl, Mirjana Weimershaus, Jan Gerstoft, Nadja Akkad, Paul Klenerman, Lars Fugger, E. Yvonne Jones, Andrew J. McMichael, Søren Buus, Hansjörg Schild, Peter van Endert, and Astrid K. N. Iversen. Antigen Processing Influences HIV-Specific Cytotoxic T Lymphocyte Immunodominance. Nat. Immunol., 10(6):636-646, Jun 2009. PubMed ID: 19412183. Show all entries for this paper.


Displaying record number 57182

HXB2 Location  Gag(77-85)   Gag Epitope Map
View variants at this location
Epitope SLYNTVATL   Epitope Alignment
Variants
SLYNTVAvL   diminished HLA binding or increased off-rate; escape documented in this paper; literature escape; susceptible form
{k}SLfNTVAvL   literature escape
{k}SLfNTiAvL   literature escape
{k}SLYNTVATL   literature escape
SLfNTVATL   escape documented in this paper; literature escape; susceptible form
{k}SLfNTiATL   literature escape
{k}SLfNTVATL   literature escape
SLYNTiATL   diminished HLA binding or increased off-rate; diminished response; escape documented in this paper; literature escape; susceptible form
SLYNTiAvL   diminished HLA binding or increased off-rate; escape documented in this paper; literature escape; susceptible form
Epitope Name SL9
Species (MHC/HLA human(A*02:01)

Variant Details

Showing all: 9 variant(s).


Variant ID.  2963
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTVAvL
Mutations T/V
Epitope Location T9V
HXB2 Location T85V
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
LE: literature escape
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding, Sequence
Note CTL selection at TCR contact residues is predicted to drive SL9 (SLYNTVATL) to SLYNTVAvL, reversion to SL9 is predicted to result from selection for optimal viral growth. This variant did not bind HLA-A*02 in vitro; and could not elicit response in 2/3 chronically-infected, untreated patients, but showed a complete EliSpot response in the other patient when compared to that elicited by wt peptide SL9. The authors designate all T84V-mutation containing peptides to be escapes.


Variant ID.  2965
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {k}SLfNTVAvL
Mutations -/K Y/F T/V
Epitope Location -1K Y4F T9V
HXB2 Location -77K Y80F T85V
Mutation Type LE: literature escape
Epitope Subtype B
Variant Subtype B
Method Sequence
Note CTL selection at TCR contact residues is predicted to drive {k}SLYNTVAvL (SL9-V) to {k}SLfNTVAvL (SL9-KFV); reversion to SL9-V is predicted to result from selection for optimal viral growth.


Variant ID.  2966
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {k}SLfNTiAvL
Mutations -/K Y/F V/I T/V
Epitope Location -1K Y4F V7I T9V
HXB2 Location -77K Y80F V83I T85V
Mutation Type LE: literature escape
Epitope Subtype B
Variant Subtype B
Method Sequence
Note CTL selection at TCR contact residues is predicted to drive {k}SLfNTVAvL (SL9-KFV) or {k}SLfNTiATL(SL9-KFI) or {R}SLFNTiAvL(SL9-IV) to {k}SLfNTiAvL (SL9-KFIV), reversion to SL9-KFV is predicted to result from selection for optimal viral growth.


Variant ID.  2967
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {k}SLYNTVATL
Mutations -/K
Epitope Location -1K
HXB2 Location -77K
Mutation Type LE: literature escape
Epitope Subtype B
Variant Subtype B
Method Sequence
Note Epitope {R}SLYNTVATL is seen to vary to {k}SLYNTVATL (SL9-K).


Variant ID.  2968
Epitope Seq.  SLYNTVATL
Variant Seq.  SLfNTVATL
Mutations Y/F
Epitope Location Y3F
HXB2 Location Y79F
Mutation Type E: escape documented in this paper
LE: literature escape
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding, Longitudinal study
Note CTL selection at TCR contact residues is predicted to drive SL9 (SLYNTVATL) to SLfNTVATL (SL9-F); reversion to SL9 is predicted to result from selection for optimal viral growth. This variant showed a slight increase in EliSpot responses in 2/3 chronically-infected, untreated patients when compared to SL9.


Variant ID.  2969
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {k}SLfNTiATL
Mutations -/K Y/F V/I
Epitope Location -1K Y4F V7I
HXB2 Location -77K Y80F V83I
Mutation Type LE: literature escape
Epitope Subtype B
Variant Subtype B
Method Sequence
Note CTL selection at TCR contact residues is predicted to drive SL9-KF {k}SLfNTVATL to {k}SLfNTiATL (SL9-KFI), reversion to SL9-KF is predicted to result from selection for optimal viral growth.


Variant ID.  2970
Epitope Seq.  {R}SLYNTVATL
Variant Seq.  {k}SLfNTVATL
Mutations -/K Y/F
Epitope Location -1K Y4F
HXB2 Location -77K Y80F
Mutation Type LE: literature escape
Epitope Subtype B
Variant Subtype B
Method Sequence
Note CTL selection at TCR contact residues is predicted to drive epitope {k}SLYNTVATL (SL9) to variant, {k}SLfNTVATL (SL9-KF).


Variant ID.  2971
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTiATL
Mutations V/I
Epitope Location V6I
HXB2 Location V82I
Mutation Type DHB: diminished HLA binding or increased off-rate
DR: diminished response
E: escape documented in this paper
LE: literature escape
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding, Sequence
Note CTL selection at TCR contact residues is predicted to drive SL9 (SLYNTVATL) to SLYNTiATL (SL9-I); reversion to SL9 is predicted to result from selection for optimal viral growth. This variant shows a loss of binding to HLA-A*02 in vitro; and is unable to generate a CTL response in 1 chronically-infected, untreated patient, with slight decrease in EliSpot in 2 others as compared to wt peptide SL9. The authors refer to all V82I mutation-containing peptides as escapes.


Variant ID.  2972
Epitope Seq.  SLYNTVATL
Variant Seq.  SLYNTiAvL
Mutations V/I T/V
Epitope Location V6I T8V
HXB2 Location V82I T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
LE: literature escape
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding, Sequence
Note CTL selection at TCR contact residues is predicted to drive SL9-I (SLYNTiATL) to SLYNTiAvL (SL9-IV); reversion to SL9-I is predicted to result from selection for optimal viral growth. This variant could not bind HLA-A*02 in vitro; and did not elicit EliSpot responses in 2/3 chronically-infected, untreated patients, but it showed an increased CTL response in the third patient as compared to WT SL9. The authors designate all V82I and T84V mutation-containing peptides as escapes.

References

Tenzer2009 Stefan Tenzer, Edmund Wee, Anne Burgevin, Guillaume Stewart-Jones, Lone Friis, Kasper Lamberth, Chih-hao Chang, Mikkel Harndahl, Mirjana Weimershaus, Jan Gerstoft, Nadja Akkad, Paul Klenerman, Lars Fugger, E. Yvonne Jones, Andrew J. McMichael, Søren Buus, Hansjörg Schild, Peter van Endert, and Astrid K. N. Iversen. Antigen Processing Influences HIV-Specific Cytotoxic T Lymphocyte Immunodominance. Nat. Immunol., 10(6):636-646, Jun 2009. PubMed ID: 19412183. Show all entries for this paper.


Displaying record number 57298

HXB2 Location  Gag(77-86)   Gag Epitope Map
View variants at this location
Epitope SLYNTVATLY   Epitope Alignment
Variants
SLYNTVAvLY   diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form
SLYNTiATLY   diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form
SLYNTiAvLY   diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form
SLfNTVATLY   diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form
SLfNTiAvLY   diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form
SLfNTVAvLY   diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form
SLfNTiATLY   diminished HLA binding or increased off-rate; escape documented in this paper; susceptible form
Epitope Name SY10
Species (MHC/HLA human(A*02)

Variant Details

Showing all: 7 variant(s).


Variant ID.  2988
Epitope Seq.  SLYNTVATLY
Variant Seq.  SLYNTVAvLY
Mutations T/V
Epitope Location T8V
HXB2 Location T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant SLYNTVAvLY could not bind HLA-A*02 in vivo; but did elicit ex-vivo EliSpot responses in at least 1 of 3 chronically-infected, untreated patients. The authors refer to all T84V mutation-containing peptides as escapes.


Variant ID.  2989
Epitope Seq.  SLYNTVATLY
Variant Seq.  SLYNTiATLY
Mutations V/I
Epitope Location V6I
HXB2 Location V82I
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant SLYNTiATLY could not bind HLA-A*02 in vivo; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients. The authors refer to all V82I mutation-containing peptides as escapes.


Variant ID.  2990
Epitope Seq.  SLYNTVATLY
Variant Seq.  SLYNTiAvLY
Mutations V/I T/V
Epitope Location V6I T8V
HXB2 Location V82I T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant SLYNTiAvLY could not bind HLA-A*02 in vivo; but did elicit ex-vivo EliSpot responses in at least 1 of 3 chronically-infected, untreated patients. The authors refer to all V82I and T84V mutation-containing peptides as escapes.


Variant ID.  2991
Epitope Seq.  SLYNTVATLY
Variant Seq.  SLfNTVATLY
Mutations Y/F
Epitope Location Y3F
HXB2 Location Y79F
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant SLfNTVATLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients. The authors refer to all Y79F mutation-containing peptides as escapes.


Variant ID.  2992
Epitope Seq.  SLYNTVATLY
Variant Seq.  SLfNTiAvLY
Mutations Y/F V/I T/V
Epitope Location Y3F V6I T8V
HXB2 Location Y79F V82I T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant SLfNTiAvLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients. The authors refer to all Y79F, V82I and T84V mutation-containing peptides as escapes.


Variant ID.  2993
Epitope Seq.  SLYNTVATLY
Variant Seq.  SLfNTVAvLY
Mutations Y/F T/V
Epitope Location Y3F T8V
HXB2 Location Y79F T84V
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant SLfNTVAvLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 1 of 3 chronically-infected, untreated patients. The authors refer to all Y79F mutation-containing peptides as escapes.


Variant ID.  2994
Epitope Seq.  SLYNTVATLY
Variant Seq.  SLfNTiATLY
Mutations Y/F V/I
Epitope Location Y3F V6I
HXB2 Location Y79F V82I
Mutation Type DHB: diminished HLA binding or increased off-rate
E: escape documented in this paper
SF: susceptible form
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant SLfNTiATLY could not bind HLA-A*02 in vitro; but did elicit ex-vivo EliSpot responses in at least 2 of 3 chronically-infected, untreated patients. The authors refer to all Y79F mutation-containing peptides as escapes.

References

Tenzer2009 Stefan Tenzer, Edmund Wee, Anne Burgevin, Guillaume Stewart-Jones, Lone Friis, Kasper Lamberth, Chih-hao Chang, Mikkel Harndahl, Mirjana Weimershaus, Jan Gerstoft, Nadja Akkad, Paul Klenerman, Lars Fugger, E. Yvonne Jones, Andrew J. McMichael, Søren Buus, Hansjörg Schild, Peter van Endert, and Astrid K. N. Iversen. Antigen Processing Influences HIV-Specific Cytotoxic T Lymphocyte Immunodominance. Nat. Immunol., 10(6):636-646, Jun 2009. PubMed ID: 19412183. Show all entries for this paper.


Displaying record number 57304

HXB2 Location  Gag(82-91)   Gag Epitope Map
View variants at this location
Epitope IAVLYCVHQR   Epitope Alignment
Variants
IvVLYCVHQR   observed variant
Epitope Name IR10
Species (MHC/HLA (A*11)

Variant Details

Showing all: 1 variant(s).


Variant ID.  2964
Epitope Seq.  IAVLYCVHQR
Variant Seq.  IvVLYCVHQR
Mutations A/V
Epitope Location A2V
HXB2 Location A83V
Mutation Type OV: observed variant
Epitope Subtype B
Variant Subtype B
Method CD8 T-cell Elispot - IFNy, HLA binding
Note Variant A11-VR10, IvVLYCVHQR, may also be present and is restricted by the same HLA, A*11.

References

Tenzer2009 Stefan Tenzer, Edmund Wee, Anne Burgevin, Guillaume Stewart-Jones, Lone Friis, Kasper Lamberth, Chih-hao Chang, Mikkel Harndahl, Mirjana Weimershaus, Jan Gerstoft, Nadja Akkad, Paul Klenerman, Lars Fugger, E. Yvonne Jones, Andrew J. McMichael, Søren Buus, Hansjörg Schild, Peter van Endert, and Astrid K. N. Iversen. Antigen Processing Influences HIV-Specific Cytotoxic T Lymphocyte Immunodominance. Nat. Immunol., 10(6):636-646, Jun 2009. PubMed ID: 19412183. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health